In a recent paper, researchers described the development of a novel oncolytic virus (OV) called OV-mOX40L for the treatment of pancreatic cancer (Figure 1). The study aimed to combine the direct oncolytic effect of OV with the immune-stimulating activity mediated by OX40L, a protein that activates T cells. The researchers conducted experiments using a syngeneic mouse model of pancreatic cancer (KPC mice) to evaluate the efficacy of OV-mOX40L. They analyzed the tumor microenvironment (TME) and performed various assays to assess T-cell response, tumor growth, and survival.
The results showed that OV-mOX40L effectively delayed tumor growth and extended survival time in the mouse model compared to the parental oncolytic virus. OV-mOX40L treatment increased T-cell infiltration, promoted an activated state in the TME, remodeled the stromal matrix, and enhanced the T-cell response. The study demonstrates that OX40L-armed OV therapy can boost T-cell
Identification of Major Signaling Changes after OV-mOX40L Therapy
The paper analyzed the effect of OV-mOX40L therapy in pancreatic cancer in mice. They identified significantly different signaling pathways between the PBS and OV-mOX40L groups. The IL6:IL6R/gp130 and PDCD1:PD-L1 signaling networks were inferred among different cell populations. The upregulation of these pathways could negatively impact anti-tumor immunity, suggesting the potential for combination therapy with neutralizing antibodies against IL6 or PD-L1 pathways.
Tumor-Infiltrating Immune Cells and Fibroblasts after Oncolytic Virus Treatment
The study analyzed tumor-infiltrating immune cells and cancer-associated fibroblasts (CAFs) after treatment with oncolytic viruses. OV-mOX40L treatment reduced Treg counts, increased the proportion of proliferated CD4 T cells, and activated CD8+ T cells while mitigating CD8+ T cell exhaustion. The treatment also induced a shift in macrophages from anti-inflammatory to pro-inflammatory and decreased the number of fibroblast active protein (FAP)-expressing CAFs.
Cell-Cell Communications in Pancreatic Cancer
The paper performed unbiased cell-cell interaction inference analysis to analyze the global alterations in cell-cell communications in pancreatic cancer. They identified the signaling communication pathways with the highest interaction strength ratios in the PBS and OV-mOX40L groups. The OV-mOX40L treatment showed increased intercellular IL6 signaling interactions among macrophages, DCs, Tregs, and iCAFs, as well as enhanced PD-L1 pathway interactions among immune cells.
The study demonstrated that OV-mOX40L treatment reinvigorated intra-tumoral immune cells, remodeled the tumor microenvironment, and enhanced the T cell response in pancreatic cancer. The treatment significantly prolonged the survival of PDAC mice, either as a monotherapy or in combination with synergistic antibodies. The results suggest a multimodal therapeutic strategy for pancreatic cancer treatment, targeting pathways such as VEGF:Flt1/Flt4/Kdr, PDCD1:PD-L1, and IL6:IL6R/gp130.
Journal article: Liu, S., et al., 2023. OX40L-Armed Oncolytic Virus Boosts T-cell Response and Remodels Tumor Microenvironment for Pancreatic Cancer Treatment. Theranostics.
Summary by Dounia Chraa